Edgewise Therapeutics
EWTX
39.57
-0.45
-1.12%
Edgewise Therapeutics
US · EWTX
#2209 by market cap
Listed 2021
39.57
-0.45
-1.12%
Live - 5344 symbols - heartbeat 191s ago
· 2026-10-07 19:54
After-hours
40.26
+1.74%
- Market cap
- 4.30B
- P/E (TTM)i
- -21.39
- P/Bi
- 9.59
- EPSi
- -1.63
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on EWTX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 8 analysts
Buy
Avg price target
55.83 +41.1%
Price target rangecurrent 39.57
Low51.00
Avg55.83
High60.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-23 | Truist Financial | -- | BUY | -- |
| 2026-09-23 | Wedbush | -- | BUY | 53.00 |
| 2026-09-23 | Leerink Partners | -- | BUY | -- |
| 2026-09-23 | H.C. Wainwright | -- | BUY | 57.00 |
| 2026-09-22 | RBC Capital | -- | BUY | 59.00 |
| 2026-09-21 | H.C. Wainwright | -- | BUY | 57.00 |
| 2026-09-01 | RBC Capital | -- | BUY | 59.00 |
| 2026-08-27 | RBC Capital | -- | BUY | 59.00 |
| 2026-08-20 | J.P. Morgan | -- | BUY | 60.00 |
| 2026-08-19 | J.P. Morgan | -- | BUY | 60.00 |
| 2026-08-07 | Evercore | -- | BUY | 55.00 |
| 2026-08-06 | RBC Capital | -- | BUY | 59.00 |
| 2026-07-20 | Evercore | -- | BUY | 55.00 |
| 2026-07-09 | Oppenheimer | -- | BUY | 51.00 |
| 2026-07-06 | Guggenheim | -- | BUY | 51.00 |
| 2026-06-17 | Truist Financial | -- | BUY | -- |
| 2026-06-17 | Wedbush | -- | BUY | 52.00 |
| 2026-06-17 | Guggenheim | -- | BUY | 41.00 |
| 2026-06-17 | RBC Capital | -- | BUY | 59.00 |
| 2026-06-16 | Leerink Partners | -- | BUY | 52.00 |
| 2026-06-16 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-06-05 | J.P. Morgan | -- | BUY | 53.00 |
| 2026-06-03 | Truist Financial | -- | BUY | 52.00 |
| 2026-06-03 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-06-02 | Truist Financial | -- | BUY | -- |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q1 | 2026-05-07 | -- | ±10.85% | -3.81% (in line) |
| 2025/Q3 | 2025-11-06 | -- | ±30.96% | -1.61% (in line) |
| 2025/Q2 | 2025-08-07 | -- | ±11.99% | -4.18% (in line) |
| 2025/Q1 | 2025-05-08 | -- | ±12.69% | +1.24% (in line) |
| 2024/Q3 | 2024-11-07 | -- | ±13.03% | -3.25% (in line) |
| 2024/Q2 | 2024-08-08 | -- | ±32.19% | +1.95% (in line) |
| 2024/Q1 | 2024-05-09 | -- | -- | -4.26% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.